ICU sedation, delirium & recovery
Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis
Authors' conclusion
Trial results at low risk of bias showed that dexmedetomidine might reduce occurrences of SAEs and delirium, while no conclusive evidence was found for effects on all-cause mortality.
Study context
- Population
- Adults in ICU or post-operative care units
- Participants
- 15,745 adults · 81 RCTs
- Comparison
- Dexmedetomidine vs placebo/no intervention
- Outcome
- Occurrence of serious adverse events (SAEs), delirium and all-cause mortality
Methodological detailsTrial Sequential Analysis, GRADE
- Trial Sequential Analysis
- GRADE
Pooled result
As reported in the abstract
Primary outcomes, trials at low risk of bias
Dexmedetomidine vs Placebo/no interventionRelative risk (95% CI)
Most frequently reported SAEs
0.69(0.43–1.09)
Cumulated SAEs
0.70(0.52–0.95)
Delirium; very low certainty of evidence
0.62(0.43–0.89)
All-cause mortality (0.4% vs 1.0%); not conclusive
0.47(0.18–1.21)
Safety
| Outcome | RR (95% CI) | |
|---|---|---|
| SAEs (trials at low risk of bias)Dexmedetomidine vs Placebo/no intervention · most frequently reported SAEs | 0.69 (0.43–1.09) | |
| SAEs (trials at low risk of bias)Dexmedetomidine vs Placebo/no intervention · cumulated SAEs | 0.70 (0.52–0.95) | |
| 0.512Relative risk (log scale) |
Original publication
Dexmedetomidine for the prevention of delirium in adults admitted to the intensive care unit or post‐operative care unit: A systematic review of randomised clinical trials with meta‐analysis and Trial Sequential Analysis. Acta Anaesthesiol Scand. Published 7 February 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →